Awakening immunity against cancer:a 2017 primer for clinicians

摘要:

Cancer immunotherapy has finally joined the pillars of cancer treatment—surgery, radiation, chemotherapy, hor-monal therapy, and targeted therapy—in improving cancer patient lives. In the last 5 years, the development of immune checkpoint inhibitor and T cell therapy, particularly chimeric antigen receptor (CAR) T-cell therapy, has been remarkable for the speed, scale, and number of drug approvals. Still, these treatments may also bring unusual adverse effects and clinical outcomes including unprecedented long-term survival. Interrogating the tumor microenviron-ment and identifying better biomarkers hold the key to improving cancer immunotherapies. CAR T-cell therapy has dramatic effect on leukemias and lymphomas with significant cure rates, but has yet to show comparable effect on solid tumors. Cutting-edge technology will improve both processing and clinical effect of such therapies. Asia has the largest, most rapidly aging population and the largest number of cancer patients in the world. Research and develop-ment and clinical trial conduct of cancer immunotherapy in Asia remain nascent, but should be a crucial priority.

更多
作者单位: National Cancer Centre Singapore,11 Hospital Drive,Singapore 169610,Singapore [1] GSR Ventures,Singapore 048762,Singapore [2] National Cancer Centre Singapore,11 Hospital Drive,Singapore 169610,Singapore;Tessa Therapeutics,Singapore 038988,Singapore [3]
期刊: 《癌症(英文版)》2017年36卷12期 672-676页 ISTICCA
栏目名称: Editorial
DOI: 10.1186/s40880-017-0233-4
  • 浏览:1
  • 下载:0

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!